Each Year, an Estimated 600 People Are Diagnosed With Adrenocortical Carcinoma Bolstering Growth of the Adrenocortical Carcinoma Treatment Market
In January 2019, Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, has announced the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma. The high prevalence of adrenal cortical carcinoma is a prime factor contributing to the growth of the adrenocortical carcinoma treatment market . According to the American Society of Clinical Oncology (ASCO), each year, an estimated 600 people are diagnosed with adrenocortical carcinoma. This type of cancer is much less common than an adrenal adenoma, a benign tumor that is found most commonly in middle-aged and older adults. The average age of a person diagnosed with an adrenal gland tumor is 46. Advancement in the diagnosing and treatment of adrenocortical carcinoma is ag...